 ADC Therapeutics SA NYSE:ADCT, a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates ADCs with highly potent and targeted pyrrolobenzodiazepine PBD dimer technology, today announced maturing data from LOTIS 2, a pivotal Phase 2 clinical trial of loncastuximab tesirine Lonca, formerly ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL, including an overall response rate of 48.3, a complete response rate of 24.1 and manageable toxicity. The Company also announced interim results from LOTIS 3, a Phase 12 clinical trial of Lonca combined with ibrutinib, which highlight the potential of Lonca to advance into earlier lines of therapy in combination with other therapies. The data are being presented in an oral presentation and e-Poster at the virtual 25th Congress of the European Hematology Association EHA25. 